tbuckley/cabot-search huggingface dataset:
Combination Chemotherapy with CHOP-Daclizumab in HTLV-I Associated Adult T-Cell Leukaemia/Lymphoma.
Authors: S. Simpson, M. Thanigaikumar, G. Taylor, E. Matutes, P. Fields, S. Devereux, A. Ho, G.J. Mufti, A. Pagliuca
Journal: Blood (2006)
Prognostic Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem Cell Transplantation At the Era of Preemptive Therapy.
Authors: Martin Schmidt-Hieber, Myriam Labopin, Dietrich Beelen, Liisa Volin, Gerhard Ehninger, Jürgen Finke, Gerard Socie, Rainer Schwerdtfeger, Nicolaus Kröger, Arnold Ganser, Dietger Niederwieser, Ulrike Feldmann, Carlheinz Müller, Emanuelle Polge, Igor Wolfgang Blau, Mohamad Mohty
Journal: Blood (2012)
CD11b-Donor Dendritic Cells Elevate Donor T-Cell Production of Interferon-Gamma and Graft-Versus-Leukemia Activity in Allogeneic Bone Marrow Transplantation.
Authors: Jian-Ming Li, Lauren Southerland, Cindy Giver, Doug McMillion, Wayn Harris, David L. Jaye, Ned Waller
Journal: Blood (2007)
Increased Liver Iron Concentration (LIC) in Adults with Non-Transfusion Dependent Sickle Cell Disease (NTD-SCD): Correlation with Serum Ferritin Concentrations
Authors: Mohamed A. Yassin, Ashraf Tawfiq Soliman, Vincenzo Desanctis, Abdulqadir Nashwan, Abbas Moustafa, Halima Elomry
Journal: Blood (2015)
PWE-142 State of The Endoscopy Services in Bangladesh- First Nationwide Survey
Authors: MM Rahman, MM Rahman, UR Dave, MJ Hossain, MG Kibria, M Nuruzzaman, F Ahmed, A Rowshon, M Hasan
Journal: Gut (2016)

<h3>Introduction</h3> We conducted survey on endoscopy centres in Bangladesh with the aim to assess the current status and to identify areas to improve standards in services. <h3>Methods</h3> All endoscopy centres in the country were identified from endoscope vendors, Bangladesh Gastroenterology society (BGS) member list and personal communication. A Structured questionnaire containing mainly structural, process and outcome measures along with a letter from BGS were sent to a senior endoscopist of every centre who completed the questionnaire. Data was analysed anonymously. <h3>Results</h3> Questionnaire sent to all 197 endoscopy centres and 195 centres responded (response rate 99%). Of those 12% were public and 88% were privately run endoscopy centres. More than half (52%) were diagnostic centres (39%) or clinics (13%) and rest were in hospital setting (48%). Gastroscopy, colonoscopy, flexible sigmoidoscopy, ERCP and EUS were done at 100%, 65%, 37%, 13% and 2% centres. Total 356251 gastroscopy, 51252 colonoscopy, 10824 flexible sigmoidoscopy, 4123 ERCP and 291 EUS were done in the year (October 2014 to September 2015) with a rate of 227, 33, 6.9, 2.63 and 0.19 per 100,000 people respectively. Majority performed only diagnostic gastroscopy (53%) in a single room unit (76%) with no dedicated recovery areas and majority never used sedation (59%). Paediatric Gastroenterologists available in 2% of 61% centres performing endoscopy on children. Computerised reports with photo provided by 97% centres and majority kept records (92%). 38% of centres were run by a single endoscopist while 9% had five or more endoscopists. Only 5% of centres had trainee endoscopists. Majority did not have registered endoscopy nurse (59%) or clerical staff (52%). Most centres had single scope (Gastroscope 76%, colonoscope 78%). Automated sterilisation system available in 3 centres and 31% reported sterilisation before procedures. Centres using sedation (41%) only 43% of them kept antidotes for sedative agents. Information leaflet for gastroscopy and colonoscopy provided by 34% and 65% and signed consent form by 35% and 80% centres respectively. Few kept records of procedure related complications (26%) and only 18% carried out regular audit. <h3>Conclusion</h3> This first ever nationwide survey on endoscopy centres provided baseline data. The study is exploring the current status and standards in endoscopy in Bangladesh which will help to identify the limitations and scope for improvements and act as a first building block. <h3>Disclosure of Interest</h3> None Declared
Long-Term Follow-up of a Randomized Trial Comparing Cyclosporine and Short Course Methotrexate with Cyclosporine and Mycophenolate Mofetil for Graft Versus Host Disease Prophylaxis in Myeloablative HLA-Identical Sibling Hematopoietic Cell Transplantation.
Authors: Betty K. Hamilton, Brian J. Bolwell, Matt Kalaycio, Lisa Rybicki, Rabi Hanna, Ronald Sobecks, Brad Pohlman, Steven Andresen, Robert M Dean, Hien K. Duong, Brian T. Hill, Edward A. Copelan
Journal: Blood (2012)
THU0553 Relationship between Active Disease and Fibromyalgia in Patients with Rheumatoid Arthritis: Table 1.
Authors: A. Kılıcaslan, F.G. Yurdakul, H. Bodur
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is an inflammatory disease characterized by erosive synovitis. Fibromyalgia syndrome (FMS) known with widespread pain, fatigue, sleep disturbances and mood disorders. FMS frequency increased in patients with RA. <h3>Objectives</h3> This study aimed to assess the prevalence of FMS in patients with RA and to analyse the relationship between disease activity and FMS. <h3>Methods</h3> The study included 151 RA patients and 77 controls without inflammatory rheumatic diseases. RA patients and the control group were evaluated with 2010 ACR criteria for FMS. Participants were divided into 4 groups according to presence of RA and FMS (Group 1: RA+, FMS+; Group 2: RA+, FMS-; Group 3: RA-, FMS+; Group 4: RA-, FMS-). Demographic characteristics, laboratory results, VAS pain, DAS 28, and HAQ scores were compared between 4 groups. RA patients were classified as in remission or without according to the DAS 28 score (DAS 28≤2.6 and&gt;2.6 respectively) and FMS evaluated. <h3>Results</h3> The mean age and sex distribution were similar between the RA patients and controls. FMS was found in 35.1% of RA patients and 19.5% of controls (p&lt;0.05). The highest VAS pain and DAS 28 scores were in the group 1 and group 3 between the sub-groups (Table 1). FMS were compared between controls, RA patients in remission and active disease. FMS ratio was 19.5%; 8.1%; 53.9% respectively (p&lt;0.05). Four parameters (ESR, tender joints, swollen joints, patient global assessment) of DAS 28 were higher in RA patients with active disease (p&lt;0.05). <h3>Conclusions</h3> FMS is more common in the patients with RA than the general population therewithal FMS found more common in the patients with active RA. When DAS 28 parameters are analyzed, objective values (ESH; swollen joint) were higher as subjective values (pain) in this group. In conclusion increased widespread pain and disruption of the sleep quality because of inflammation may facilitate the diagnosis of FMS. <h3>References</h3> Zammurrad S, Munir W, Farooqi A. Disease activity score in rheumatoid arthritis with or without secondary fibromyalgia. J Coll Physicians Surg Pak. 2013 Jun;23(6):413–7. Toms J, Soukup T, Bradna P, Hrncir Z. Disease activity composite indices in patients with rheumatoid arthritis and concomitant fibromyalgia. J Rheumatol. 2010 Feb;37(2):468 <h3>Disclosure of Interest</h3> None declared
Addition of R-HMA to R-DA-EPOCH Favourably Changes the Outcome in Patients with Untreated High-Grade Diffuse Large B-Cell Lymphoma: The First Results of Russian Prospective Multicenter Trial
Authors: Olga A. Gavrilina, Eugene E. Zvonkov, Elena N. Parovichnikova, Vera V. Troitskaya, Nelly G. Gabeeva, Andrey V. Gubkin, Larisa A. Kuzmina, Valery A. Lapin, Inessa Yu. Toropova, Vitalii S. Kanin, Valeri G. Savchenko
Journal: Blood (2015)
BH3 Profiling As Predictor Of 5-Azacytidine and Decitabine Clinical Responses
Authors: Raoul Tibes, Steven M. Kornblau, William E. Pierceall, Ryan Lena, Yi Hua Qiu, Michael Cardone, Leena Chaudhuri, Veena Fauble, Michael Elashoff, Noel Blake, Ruben A. Mesa, James M Bogenberger
Journal: Blood (2013)
IMST-07. LOCAL REGULATED IL-12 EXPRESSION AS AN IMMUNOTHERAPY FOR THE TREATMENT OF PONTINE GLIOMA
Authors: John Barrett, Hongliang Cai, John Miao, Karah Ludington, Courtney Devore, Paul Gonzales, Sam Broder, Francois Lebel, Laurence Cooper
Journal: Neuro-Oncology (2016)

Diffuse intrinsic pontine gliomas (DIPG) account for 10-25% of pediatric brain tumors with a grim median survival time of <1 year. Immunotherapy may be an attractive approach for DIPG, however, the lack of defined tumor antigens with homogeneous expression that may be safely targeted has handicapped this approach. Therefore, we have implemented clinical trials to recruit and stimulate the endogenous immune response by local delivery of a replication-incompetent adenovirus engineered to conditionally express IL-12, via our RheoSwitch Therapeutic System® (RTS®) gene switch (Ad-RTS-IL-12). Previous studies in supratentorial syngeneic mouse tumor models demonstrated that Ad-RTS-mIL-12+veledimex elicited a dose-related increase in tumor IL-12 mRNA resulting in IL-12 protein and downstream IFN-g which correlated with increased anti-tumor effects and survival. In ongoing clinical trials with Ad-RTS-hIL-12+veledimex within recurrent supratentorial gliomas, we observed encouraging improvement in overall survival and a moderate toxicity profile readily manageable by stopping veledimex. The effects of vehicle alone, Ad-RTS-mIL-12 (5x109vp intratumoral) +vehicle, Ad-RTS-mIL-12+veledimex 30 to 300 mg/m2/day,po QDx14 and temozolomide 300mg/m2,po QDx5 were studied. in GL261 medullary glioma model with 3x105 GL261 cells placed in the pontine region (5mm caudal Bregma, 1mm lateral, depth of 3.5mm Pons) 5 days prior to initiation of therapy and the animals monitored for up to 85 days posttreatment. Ad-RTS-mIL-12+veledimex 30, 100, and 300mg/m2/day elicited increases in tumor IL-12 at Day 3 of 50, 197 and 253pg/mg, respectively. At Day 85 (study termination), the percent of surviving animals was 50, 42, and 83%, respectively with 9/10 tumor free at 300mg/m2/day. Median survival for vehicle was 16 days; Ad-RTS-mIL-12 21 days; and temozolomide 25 days. Ad-RTS-mIL-12+veledimex demonstrated increased in survival without significant adverse events. Controlled delivery of IL-12 appears to be an effective for DIPG. Based on these results a Phase I clinical trial in pediatric DIPG is planned for 2017.
PTU-016 The Endoscopic Submucosal Dissection Learning Curve: The Experience of a Large Volume Italian Colorectal (CRC) Screening Centre
Authors: E Rosa-Rizzotto, E Guido, D Caroli, A Dupuis, M Lo Mele, M Rugge, P Pilati, F De Lazzari
Journal: Gut (2016)

<h3>Introduction</h3> Endoscopic submucosal dissection (ESD) is an advanced endoscopic technique. In Eastern countries the learning curve is begun with gastric GI lesions carried out under expert supervision and then goes on to address esophageal and colon lesions. As Early Gastric Cancer (EGC) is a rare disease in Western countries, expert guidance is not commonly available. <h3>Methods</h3> All the ESD performed in our Endoscopy Unit in Padua from February 2012 to December 2015 including 12,552 colonoscopies were recruited retrospectively in this study. We considered the learning curve of a single endoscopist who performed 10 ESD on in vivo animal models under expert supervision before starting on human subjects. All the dissections were performed using a Hybridknife needle and ERBEJET2 (ERBE®). ESD was performed if the neoplastic lesion was considered susceptible to ESD regardless to the size. T tests for unpaired data and Pearson’s chi-test were used for statistical analysis. <h3>Results</h3> 49 ESD were performed, 28 M(57%), mean age 63 yr. The breadown was: 29 rectum (59%), 12 sigmoid tract (24%), 2 trasverse colon (4%), 4 ascending colon (8%), 2 stomach (4%). The neoplastic lesions were: 36 laterally spreading tumours (73%), 5 polypoid lesions 0 Is (10%), 4 recurrent ton scars (8%), 4 polypoid lesions 0 Isp(10%). Mean polyp area was 17.6 cm<sup>2 </sup>(range 1–70). Mean intervention time was 98 min (range 20–240). En-bloc dissection was successful in 34/49 (69%) and R0 was reached in 24/33 (72%). The histological features of the polyps were: 10 LGD (20%), 27 HGD (55%), 9 pT1 (18%), 3 pT2 (6%). The procedural complications that took place (14/49 = 28%) included: perforation during the procedure in 10/49 (20%), delayed bleeding in 3/49 (6%), rectal stenosis in 3/49 (6%). No deaths or surgical interventions followed the periprocedural complications. From the 12<sup>th</sup> procedure onwards the surgical performance became acceptable 22/27 (81%) vs 3/12 (25%) (p &lt; 0.001). From the 30<sup>th</sup> procedure onwards the surgical performance became good 17/19 (90%, p &lt; 0.05) and the mean execution time was significantly lower 55 vs 122 min (p &lt; 0.0001) with no significant difference in the mean area of the lesions 15.6 vs 18.2 cm<sup>2 </sup>(p=ns). Only 3 complications occurred after the 30<sup>th</sup> procedure (p=ns). <h3>Conclusion</h3> Our findings demonstrate than an endoscopist can reach a satisfactory level of competence in ESD procedures by beginning training with in vivo animal models (at least 10 procedures) and then should go on to colo-rectal neoplasms (without size limits and no less than 12 procedures). Trainees have probably still not reached a learning curve plateau even after 40 procedures. <h3>Disclosure of Interest</h3> None Declared
Exosomes in immunoregulation of chronic lung diseases
Authors: K. P. Hough, D. Chanda, S. R. Duncan, V. J. Thannickal, J. S. Deshane
Journal: Allergy (2016)

Exosomes are nano-sized, membrane-bound vesicles released from cells that transport cargo including DNA, RNA, and proteins, between cells as a form of intercellular communication. In addition to their role in intercellular communication, exosomes are beginning to be appreciated as agents of immunoregulation that can modulate antigen presentation, immune activation, suppression, and surveillance. This article summarizes how these multifaceted functions of exosomes may promote development and/or progression of chronic inflammatory lung diseases including asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis. The potential of exosomes as a novel therapeutic is also discussed.
Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results
Authors: Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian Flinn, Marshall T. Schreeder, Nathan Fowler, Jeff P. Sharman, Ralph V. Boccia, Jaqueline C. Barrientos, Kanti R. Rai, Thomas E Boyd, Richard R. Furman, Leanne M. Holes, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Journal: Blood (2014)
PWE-079 Raman Spectroscopycancer Diagnostic for Pathology of Barrett’s Oesophagus
Authors: H Barr, M Isabelle, O Old, G Lloyd, K Lau, J Dorney, A Lewis, T Geraint, N Shepherd, I Bell, N Stone, C Kendall
Journal: Gut (2016)

<h3>Introduction</h3> Raman spectroscopy has been shown to accurately classify tissue pathology in a variety of conditions and organ systems. Much of this work has been performed using Raman microspectrometers on tissue sections. Despite the demonstrated potential as an accurate cancer diagnostic tool, Raman spectroscopy (RS) is yet to be adopted by the clinic for histopathology reviews. The Stratified Medicine through Advanced Raman Technologies (SMART) consortium has begun to address some of the hurdles (e.g. tissue sample preparation, data collection, pre-processing and transferability) in its adoption for cancer diagnosis. SMART is a multicentre industry-academic collaboration with the aim of developing a pathology platform for advanced diagnosis, using developments in hardware and software. Renishaw’s Streamline™ Raman technology enables collection of Raman spectral much faster without compromising signal to noise. This study aims to assess the ability of this technique to accurately classify tissue pathology, using an oesophageal model. <h3>Methods</h3> Specimens were collected from patients with Barrett’s oesophagus (BO), dysplasia and adenocarcinoma, and snap frozen in liquid nitrogen. 8μm tissue sections were prepared onto calcium fluoride slides, with contiguous sections stained with haematoxylin and eosin (H&amp;E) for histological comparison. Raman spectra were collected across homogeneous regions of tissue pathology, using Streamline™ acquisitions of 60 seconds/line, at 1.1μm spatial resolution. <h3>Results</h3> Advanced multivariate statistical analysis tools were used to develop pathology classification models, which were then tested using leave-one-out cross-validation. Each sample was then classified using a ‘voting classification’ for all pixels from one sample. The sensitivity and specificity of this pathology classification model using Raman Spectroscopy to discriminate dysplasia/adenocarcinoma from Barrett’s oesophagus produced sensitivity and specificities &gt;80%. <h3>Conclusion</h3> By combining multivariate statistical analysis with Streamline™ Raman acquisition of spectral data, we have demonstrated good sensitivities and specificities. This study illustrates the potential of non-invasive rapid Raman spectral mapping measurements and development of a robust and validated oesophageal classification model that are able to classify tissue pathology. <h3>Disclosure of Interest</h3> None Declared
588. PK-7 and RD2-MolPack-Chim3.14, Two Packaging Cell Clones for Semi-Stable and Stable Production of HIV-Based Lentiviral Vectors
Journal: Molecular Therapy (2011)

1. Porcellini S, Alberici L, Gubinelli F, et al. The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration. Blood. 2009;113:3443-3452. 2. Porcellini S, Gubinelli F, Alberici L, Piovani BM, Rizzardi GP, Bovolenta C. Chim3 confers survival advantage to CD4+ T cells upon HIV-1 infection by preventing HIV1 DNA integration and HIV-1-induced G2 cell-cycle delay. Blood. 2010;115:40214029.. 3. Di Nunzio F, Piovani B, Cosset FL, Mavilio F, Stornaiuolo A. Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein. Hum Gene Ther. 2007;18:811-820. Summary
Clonal Analyses of Retroviral Vector Integrations in ADA-SCID Patients Treated with Stem Cell Gene Therapy.
Authors: Barbara Cassani, Grazia Andolfi, Massimiliano Mirolo, Luca Biasco, Alessandra Recchia, Fabrizia Urbinati, Cristina Valacca, Samantha Scaramuzza, Matteo Cazzola, Daniela Sartori, Alessandro Ambrosi, Clelia Di Serio, Maria Grazia Roncarolo, Fulvio Mavilio, Claudio Bordignon, Alessandro Aiuti
Journal: Blood (2006)
Erratum to: Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens
Authors: Thuy Doan, Michael R. Wilson, Emily D. Crawford, Eric D. Chow, Lillian M. Khan, Kristeene A. Knopp, Brian D. O’Donovan, Dongxiang Xia, Jill K. Hacker, Jay M. Stewart, John A. Gonzales, Nisha R. Acharya, Joseph L. DeRisi
Journal: Genome Medicine (2016)

Doan et al. Genome Medicine (2016) 8:123 DOI 10.1186/s13073-016-0377-x ERRATUM Open Access Erratum to: Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens Thuy Doan 1,2† , Michael R. Wilson 3,4† , Emily D. Crawford 3,5 , Eric D. Chow 3 , Lillian M. Khan 3 , Kristeene A. Knopp 3 , Brian D. O’Donovan 3 , Dongxiang Xia 6 , Jill K. Hacker 6 , Jay M. Stewart 2 , John A. Gonzales 1,2 , Nisha R. Acharya 1,2 and Joseph L. DeRisi 3* Erratum It has come to our attention that there is an error in Fig. 3a for this article [1]. The correct version of Fig. 3a can be found below. The red markers now reflect the se- quence differences. The text is correct. There was also a row omitted in Additional file 1: Table S1. The revised version can be found below. Additional file Additional file 1: Table S1. List of nucleotide substitutions identified in subject 6’s RV genome. The patient’s RV genome was aligned with the Stuttgart strain (GenBank DQ388280.1). A nucleotide change was considered a substitution only if the change was present in ≥ 4 reads or in 80% of the total reads at that nucleotide position. (PDF 120 kb) Author details Francis I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA. 2 Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA. 3 Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA. Department of Neurology, University of California San Francisco, San Francisco, CA, USA. 5 Howard Hughes Medical Institute, Chevy Chase, MD, USA. 6 California Department of Public Health, Richmond, CA, USA. Received: 7 November 2016 Accepted: 7 November 2016 Reference 1. Doan T, Wilson MR, Crawford ED, Chow ED, Khan LM, Knopp KA, O’Donovan BD, Xia D, Hacker JK, Stewart JM, Gonzales JA, Archarya NR, DeRisi JL. Illuminating uveitis: metagenomic deep sequencing identifies common and rare pathogens. Genome Med. 2016;8:106. * Correspondence: joe@derisilab.ucsf.edu Equal contributors Department of Biochemistry and Biophysics, University of California San Francisco, San Francisco, CA, USA © The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Government must not shy away from bold action on public health, says MP
Authors: Matthew Limb
Journal: BMJ (2016)

A leading Conservative MP has urged the government to take bolder action to reduce health inequalities and to not fear driving citizens “into the arms of UKIP.”

Sarah Wollaston, who chairs the health select committee and is a former GP, said that people wanted to see tougher measures being introduced that could significantly improve public health. But she feared that the recent Brexit referendum and US election results might lead ministers to back away from steps that could be “seen or interpreted as nanny state.” She said, “It’s one thing to talk the talk on health inequalities, but we now need to see the government walking the …
Ezh2 and Runx1 Mutations Targeted to Early Lymphoid Progenitors Collaborate to Promote Early Thymic Progenitor Leukemia
Authors: Christopher Booth, Nikolas Barkas, Wen Hao Neo, Elizabeth Soilleux, Hanane Boukarabila, Alice Giustacchini, Thomas Milne, Neil Ashley, Joana Carrelha, Lauren Jamieson, Deborah Atkinson, Tiphaine Bouriez-Jones, Sten Eirik Jacobsen, Adam Mead
Journal: Blood (2015)
In Vitro and in Vivo Inhibition of JAK2 Signaling by Potent and Selective JAK2 Inhibitor
Authors: Vadim Markovtsov, Elizabeth Tonkin, Shuling Fang, Chiang Liu, Marina Gelman, Wayne Lang, Jason Romero, John McLaughlin, Somasekhar Bhamidipati, Jeffrey Clough, Rajinder Singh, Caroline Low, Andrea Reitsma, Vanessa Taylor, Stacey Siu, Gary Park, David Sweeney, Polly Pine, Allan Torneros, George Clemens, Matt Duan, Ruby Daniel, Donald Payan, Sacha Holland, Yasumichi Hitoshi
Journal: Blood (2008)
Disruption of the NDE1 Gene Occurs in 90% of the Cases of inv(16) AML and Results in Chromosomal Instability and Myeloproliferative Disease in Mice.
Authors: Joop H. Jansen, Yuanyi Feng, Benjamin Lee, Marion Massop, Theo De Witte, Ifor Williams, Gary Gilliland, Chris Walsh, Bert A. van der Reijden
Journal: Blood (2004)
Independent Risk Factors of Catheter-Related Thrombosis (CRT) in Adult Cancer Patients: An Individual Patient-Level Data (IPD) Meta-Analysis of Randomized Clinical Trials and Prospective Cohort Studies
Authors: Wael Saber, Teng Moua, Eliot C. Williams, Melina Verso, Giancarlo Agnelli, Stephen Couban, Annie Young, Marcello De Cicco, Roberto Biffi, Cornelis J. van Rooden, Menno V. Huisman, Daniele Fagnani, Claudio Cimminiello, Marco Moia, Stephen P. Povoski, Sharp Malak, Agnes Y. Lee
Journal: Blood (2008)